Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,455 USD | +1,92% | -8,86% | -63,00% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 278 mln. 260 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -46 mln. -42,98 mln. | Nettowinst (verlies) 2025 * | -72 mln. -67,27 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-5,95
x | K/w-verhouding 2025 * |
-3,9
x | Werknemers | 40 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,86% |
Recentste transcriptie over Anavex Life Sciences Corp.
1 dag | +1,92% | ||
1 week | -8,86% | ||
Lopende maand | -32,32% | ||
1 maand | -28,82% | ||
3 maanden | -45,58% | ||
6 maanden | -38,70% | ||
Lopend jaar | -63,00% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 05-07-13 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 01-10-15 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 05-07-13 | |
Tom Skarpelos
FOU | Founder | 57 | 23-01-04 |
Jiong Ma
CHM | Chairman | 60 | 25-05-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.08% | 0 M€ | 0,00% | - | |
0.07% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 3,445 | +1,63% | 447 868 |
25-04-24 | 3,39 | -0,59% | 1 272 866 |
24-04-24 | 3,41 | -7,34% | 1 955 839 |
23-04-24 | 3,68 | 0,00% | 1 365 920 |
22-04-24 | 3,68 | -2,65% | 1 358 524 |
uitgestelde koers Nasdaq, 26 april 2024 om 20:53 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-63,00% | 278 mln. | |
-2,16% | 103 mld. | |
+0,69% | 95,71 mld. | |
+1,69% | 22,02 mld. | |
-16,96% | 20,9 mld. | |
-9,30% | 17,85 mld. | |
-41,01% | 16,21 mld. | |
-14,63% | 15,52 mld. | |
+3,56% | 13,86 mld. | |
+35,00% | 12,04 mld. |